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Abstract
We have mapped a disease locus for Wolff-Parkinson-White
syndrome (WPW) and familial hypertrophic cardiomyopa-
thy (FHC) segregating in a large kindred to chromosome 7
band q3. Although WPW syndrome and FHC have been
observed in members of the same family in prior studies,
the relationship between these two diseases has remained
enigmatic. A large family with 25 surviving individuals who
are affected by one or both of these conditions was studied.
The disease locus is closely linked to loci D7S688, D7S505,
and D7S483 (maximum two point LOD score at D7S505
was 7.80 at 0 = 0). While four different FHC loci have been
described this is the first locus that can be mutated to cause
both WPW and/or FHC. (J. Clin. Invest. 1995. 96:1216-
1220.) Key words: cardiomyopathy, hypertrophic * hyper-
trophy * Wolff-Parkinson-White syndrome * genetics * heart
Introduction
Wolff-Parkinson-White syndrome (WPW)' is one of the most
common congenital cardiac abnormalities with a prevalence
of 0.15-3 per 1,000 (1). WPW results from an anomalous
atrioventricular (AV) conduction pathway that can produce
ventricular preexcitation and paroxysmal reentrant tachycardias.
The syndrome is typically recognized by a short PR interval on
the surface electrocardiogram, however definitive diagnosis of
preexcitation may require electrophysiologic testing. While
most affected individuals appear to be sporadic, screening stud-
ies have suggested that at least 3% of probands have a symptom-
atic affected first degree relative ( 1). Reports of familial
WPW have demonstrated an autosomal dominant mode of in-
heritance (2-8).
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Familial hypertrophic cardiomyopathy (FHC) is an autoso-
mal dominant disorder that is characterized by unexplained ven-
tricular hypertrophy with histological evidence of myocyte and
myofibrillar disarray. Genetic studies of FHC families have
identified disease-causing mutations in cardiac troponin T on
chromosome 1 (9), /3 cardiac myosin heavy chain on chromo-
some 14 (10), and a-tropomyosin on chromosome 15 (9). A
fourth FHC locus has been described on chromosome 11 ( 11 ).
There have been no reports of individuals with FHC due to
mutations at these disease loci who also have WPW, although
5- 10% of hypertrophic cardiomyopathy patients have ventricu-
lar preexcitation ( 12). An association between these conditions
was noted in the earliest descriptions of hypertrophic cardiomy-
opathy. In 1960 Braunwald et al. (13) proposed that abnormal
ventricular activation might result in regional myocardial hyper-
trophy or that localized hypertrophy might disrupt normal car-
diac electrical discontinuity at the atrioventricular ring.
There is clinical evidence to suggest that the development
of ventricular preexcitation in individuals with FHC may be
limited to particular kindreds, and may reflect a distinct genetic
etiology. Affected individuals with both preexcitation and hy-
pertrophy often exhibit high grade AV block which is usually
regarded as an uncommon phenomenon in FHC (14-17).
Pathologic descriptions of cardiac tissues from individuals with
both disorders are also unusual in that myocardial fibrosis is
the dominant histological finding (18). To elucidate the rela-
tionship between WPW and FHC we have clinically and geneti-
cally evaluated members of a large kindred with both of these
conditions. Ventricular preexcitation and hypertrophic cardio-
myopathy segregated as a single autosomal dominant disorder
in this family. Genetic linkage analyses demonstrated that the
gene defect responsible for both conditions is located on chro-
mosome 7q3. These data identify the fifth FHC locus, but the
first disease locus for WPW.
Methods
Clinical evaluations. All clinical and genetic studies were carried out
in accordance with local institutional review committee guidelines. Sur-
viving members of Family AS (Fig. 1) were studied by review of
clinical records, history, physical exam, 12-lead electrocardiogram, and
two-dimensional echocardiogram with Doppler sonography. Each indi-
vidual with any abnormality detected by this evaluation was further
studied by 24 h Holter monitoring. Diagnosis of individual III-22 was
based on necropsy data.
FHC was diagnosed on the basis of unexplained left ventricular
hypertrophy as previously described (19-21). WPW was diagnosed
based on documented spontaneous ventricular preexcitation or a positive
adenosine test (see below). Individuals with a PR interval < 100 ms
plus an abnormal initial QRS vector or bundle branch block and individ-
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Figure 1. Family AS pedigree used for linkage analyses. Men are denoted by squares, women by circles. Affection status is indicated as follows:
half-filled symbols denote FHC (left) or WPW (right); closed symbols denote both conditions; shaded symbols denote individuals with abnormal
EKGs and normal echocardiograms; open symbols denote unaffected individuals.
uals with LVH plus an abnormal initial QRS vector were classified as
having abnormal electrocardiographic patterns with possible preexcita-
tion. For linkage analyses, individuals with any one of these traits were
considered affected.
11 family members (Table I) had intravenous adenosine testing as
described previously (22, 23). A rapid bolus of adenosine was adminis-
tered in graded doses from 0.1 to 0.5 mg/kg, with orthogonal three-
lead electrocardiographic monitoring, until block of physiologic atrio-
ventricular conduction was induced or until symptoms became limiting.
If electrocardiographic monitoring demonstrated increased ventricular
preexcitation, the test was considered positive; if complete atrioventricu-
lar block was observed the test was considered negative. Subjects who
failed to demonstrate any change in atrioventricular conduction or QRS
morphology despite bradycardia, reflex tachycardia and symptoms were
classified as indeterminate responders. We did not perform adenosine
tests on all family members as the remaining affected individuals refused
to consent to testing and we considered it unethical to administer
adenosine to those who had no evidence of cardiomyopathy or preexcita-
tion.
Genetic analyses. Peripheral blood samples obtained from each fam-
ily member were used to produce Epstein-Barr virus-transformed
lymphoblastoid cell lines, from which genomic DNA was isolated (19).
Short tandem repeat polymorphisms from throughout the genome were
amplified using the polymerase chain reaction (PCR) with published
primer nucleotide sequences and analyzed by polyacrylamide gel elec-
trophoresis as previously described (24). The genotype of individual
III-22 was reconstructed based on analyses of his spouse and three
children.
Linkage analyses. Two-point LOD scores (logarithm of the odds)
were calculated using MLNK (version 5.1 ) program assuming a pene-
trance of 0.95 and allele frequencies from published data (25, 26).
Multipoint LOD scores were calculated using the LINKAGE program
with loci D7S483, D7S505, and D7S688 using published map distances
from the consensus map of chromosome 7 (27).
Results
Clinical evaluations. 43 surviving individuals from three gener-
ations of Family AS, were clinically evaluated (Fig. 1). None
of the family members had a history of systemic hypertension.
25 family members had abnormal electrocardiograms and/or
echocardiograms. These individuals had cardiac symptoms in-
cluding chest pain, dyspnea, palpitations, and syncope (Table
I). In addition six individuals noted skeletal muscle discomfort
after exercise. Holter monitoring demonstrated a variety of dys-
rhythmias. Three required pacemaker insertion: two for symp-
tomatic complete heart block (III-i, III-7) and one individual
(III-3) for symptomatic sinoatrial disease.
19 individuals had echocardiographic evidence of hypertro-
phic cardiomyopathy (Table I and Fig. 1) with an average
maximum left ventricular wall thickness (LVWT) of 20±9 mm.
This was not significantly different (P> 0.1) from the average
LVWT of FHC patients with ,3 cardiac myosin heavy chain
gene mutations. Postmortem examination of individual 11-22
was also consistent with hypertrophic cardiomyopathy (cardiac
weight = 595 grams, histological evidence of myocyte hypertro-
Table L Clinical Characteristics ofAffected Individuals
in Family AS
ID Age/
Number Sex EKG Preexcitation LVWT Holter Clinical
mm
IE-l 52/F PR, LVH ND 14 CHB(V) C, P, D, S
111-3 58/F LBBB Adenosine/IR 26 SB, PAF(V) C, P, D, M
in-5 50/M LVH Adenosine/IR 20 SB, PAF C, P. D, S, M
E-7 47/M LBBB Adenosine/IR 19 PAF, CHB(V) D, P. S
En-8 47/M LBBB Adenosine/IR 11 SB P, D
E1-13 35/F PR Adenosine/+ 12 N C, P. D, M
m1I-16 41/F LVH ND 30 PAF C, P
E1-18 40/F PR, LVH ND 35 N C, S
IE-19 39/M LVH ND 30 N C, S
E-22 32/M LBBB ND N/A N SCD
iE-24 36/M LVH ND 15 SB C,P,S
11-25 31/M LBBB Adenosine/+ 15 SB C, P, M
m-26 33/F LBBB Adenosine/IR 20 SB C, D, M
m-27 37/F LBBB + 34 PAF C, P. D
11-30 31/M LVH Adenosine/IR 13 SB P. D, M
IV-2 23/M PR, LVH + 25 PAF C
IV-3 22/F LVH Adenosine/IR 10 N C
IV-4 12/M LVH ND 15 N C, P, S
IV-S 20/M LVH ND 10 N C
IV-6 19/F N Adenosine/- 14 N P. D, S
IV-7 17/F LBBB ND 10 N D
IV-9 18/F LVH ND 14 N A
IV-10 12/M PR,LVH ND 15 N A
IV-11 18/M LVH ND 45 N C
IV-12 19/F LBBB Adenosine/- 18 N C
EKG, electrocardiogram; PR, short PR < 100 ms; LVH, voltage criteria for left
ventricular hypertrophy; LBBB, left bundle branch block; ND, not done; IR, inde-
terminate response; LVWT, maximum left ventricular wall thickness; N/A, not
available; CHB, complete atrioventricular block; SB, sinus bradycardia; PAF,
paroxysmal atrial fibrillation; V, permanent pacemaker inserted; C, chest pain; D,
dyspnea; M, skeletal muscle pain after exertion; P. palpitations; S. syncope; A,
asymptomatic.
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Table II. Pairwise Lod Scores Reflecting Linkage between
Chromosome 7 Loci and Disease
Recombination fraction (9)
LOCUS 0.00 0.01 0.05 0.10 0.20 0.30 0.40
D7S500 -5.29 -3.04 -0.74 0.44 1.16 1.09 0.58
D7S495 -0.40 0.36 1.58 1.99 2.01 1.56 0.79
TCRB -2.37 -1.37 3.08 3.53 3.36 2.57 1.35
D7S498 -1.13 -0.77 0.49 0.94 0.94 0.61 0.29
D7S688 3.43 5.74 5.94 5.60 4.50 3.13 1.54
D7S505 7.80 7.67 7.14 6.45 4.94 3.27 1.47
D7S642 7.09 6.98 6.52 5.27 4.60 3.12 1.48
D7S636 6.18 6.08 5.67 5.13 3.96 2.64 1.21
D7S483 2.77 5.98 6.15 5.77 4.56 3.02 1.28
D7S550 -2.80 1.14 2.76 3.10 2.82 2.04 0.97
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Figure 2. Electrocardiogram of individual IV-3. Note the voltage criteria
for LVH and intraventricular conduction delay (leads V1-V3). This
typified the electrocardiographic abnormalities observed in individuals
IV-5 and IV-7.
phy with extensive fibrosis). The anatomical distribution of
myocardial hypertrophy varied in these 20 individuals but was
typical of that previously reported in FHC (28).
Two individuals (III-27 and IV-2) had previously been diag-
nosed with WPW based on episodic spontaneous preexcited
atrial fibrillation. 17 family members had electrocardiograms
suggestive of preexcitation (29) and it was possible to perform
intravenous adenosine challenges (Methods) on 11 individuals.
In seven individuals the test was inconclusive. In two individu-
als (IV-6 and IV-12) adenosine induced atrioventricular block,
suggesting an anterograde accessory pathway was not present.
In two individuals (111-13 and III-25) adenosine demonstrated
ventricular preexcitation. Both of these individuals and individ-
uals 1I1-27 and IV-2 had electrocardiographic patterns sug-
gesting right free wall accessory pathways.
Four family members with abnormal electrocardiograms
(Fig. 2) had normal echocardiograms and indeterminate (111-8,
IV-3) adenosine tests or refused (IV-5, IV-7) adenosine testing.
Individual 111-8 transmitted hypertrophic heart disease to her
daughter. These individuals were considered affected for ge-
netic analysis.
Pedigree analysis of family AS demonstrated autosomal
dominant transmission of a trait that caused hypertrophic cardio-
myopathy and/or WPW. This trait segregates with a high degree
of penetrance but variable expressivity in this family.
Genetic analyses. DNA from all affected individuals and
unaffected individuals over age 25 yr were analyzed in linkage
studies of Family AS using an autosomal dominant model of
inheritance. The known FHC loci on chromosomes 14q, lq, 11,
and 15q (19-21) were initially analyzed and at each locus
linkage was excluded (data not shown). We then assessed link-
age between highly polymorphic loci located throughout the
genome and the disease trait in Family AS. Approximately 50%
of the human genome was excluded before preliminary evidence
of linkage was detected with locus D7S500, located on the distal
q arm of chromosome 7. Linkage to nine other loci (D7S495,
TCRB, D7S498, D7S688, D7S505, D7S642, D7S636, D7S483,
and D7S550) was then assessed (Table II). The maximum
two-point LOD score, detected with locus D7S505, was 7.80
at a recombination fraction (8) of 0.0 indicating odds of
> 60,000,000 to 1 that the locus responsible for disease in
Family AS is on chromosome 7q3 (30). The physical location
of chromosome 7 anchor marker TCRB places the disease locus
at 7q35-7q36 (27).
To refine the location of disease a multipoint linkage map
was constructed using loci D7S505, D7S688, and D7S483. A
maximum multipoint LOD score of 10.2 was obtained in the
interval between D7S688 and D7S483 (Fig. 3). Figure 3B dem-
onstrates the haplotypes of individuals who exhibited recombi-
nation across this region. The disease interval defined by these
recombination events further supports the localization of the
disease gene to the interval between D7S688 and D7S483, a
distance of approximately seven centimorgans. Two additional
families, with typical FHC (without WPW), which did not map
to any of the four known FHC loci were tested with the markers
D7S688 and D7S483 and in each case linkage was definitively
excluded (data not shown).
Discussion
We report a family in which FHC and WPW are inherited as a
single autosomal dominant trait and demonstrate that the disease
locus maps to chromosome 7q3 between loci D7S688 and
D7S483. The chromosome 7 mutation in affected members of
Family AS manifests as ventricular hypertrophy, ventricular
preexcitation, or both. These genetic data confirm earlier
hypotheses that FHC and the WPW syndrome are fundamen-
tally related ( 13). Identification of the disease causing mutation
in Family AS will enable a better understanding of this relation-
ship.
Variable expressivity characterized the disorder transmitted
in Family AS. 20 individuals had hypertrophic cardiomyopathy;
4 of these individuals also had WPW. One individual had WPW
without cardiac hypertrophy. The actual number of Family AS
members with ventricular preexcitation could not be accurately
ascertained because most adenosine tests performed on these
individuals were indeterminate. In several tests the apparent
marked resistance of the AV node to adenosine which we ob-
served may represent slow baseline AV nodal conduction with
maximal preexcitation at rest. In view of these results and the
refusal of adenosine testing by many family members, it is
possible that other individuals with FHC have latent or con-
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Figure 3. (A) The multipoint LOD score curve for the three markers
D7S483, D7S505, D7S688, and disease. The origin was arbitrarily de-
fined as the marker D7S688. (B) The haplotypes of critical recombinants
across the interval from TCRB to D7S550. A black line represents
evidence of recombination between a marker and disease. A hatched
line represents non-informativeness at a given marker. Unfilled regions
represent haplotypes that are concordant with disease.
cealed accessory pathways. It is also possible that individuals
with normal echocardiograms may have a subclinical cardiomy-
opathic process which has been reported previously with WPW.
Thus, much of the apparent phenotypic variation may reflect
the resolution of the non-invasive diagnostic techniques used.
At present we do not know whether FHC or WPW in isola-
tion can be due to the gene defect on chromosome 7. However,
this study provides the first genetic locus for WPW and will
enable investigations of familial WPW without cardiomyopathy
to assess genetic heterogeneity. The clinical data on several
affected members in Family AS defined a hypertrophic cardio-
myopathy that is subtly different from FHC that is not accompa-
nied by WPW. The histopathology of the myocardium from
individual III-22 demonstrated marked fibrosis that was dispro-
portionate to myocyte hypertrophy and disarray, as has been
previously described primarily in individuals with ventricular
preexcitation and FHC. Individuals III-1 and III-7 developed
complete heart block, which is a relatively rare occurrence in
FHC yet has been reported several times when WPW was also
present ( 16, 17, 3 1 ). While a mutation that perturbs contiguous
genes at chromosome 7q3 may account for both FHC andWPW
in Family AS, the distinguishing features of the cardiomyopathy
found in Family AS and that reported in other individuals with
FHC and WPW suggest that there may be a single etiology for
both conditions.
WPW is thought to arise from failed regression of develop-
mental atrioventricular anatomical and electrical continuity
(32). FHC has been demonstrated to be due to mutations in
three different sarcomeric contractile proteins. Candidate genes
for FHC and WPW might be expected to have a role in both
processes. An actin binding protein, filamin (FLN2) which is
highly expressed in heart and skeletal muscle has been mapped
to chromosome 7q (33). Given the diverse roles of actin iso-
forms in a variety of cell types, defects in actin-associated mole-
cules such as filamin might produce the FHC/WPW phenotype.
S483 Two other genes encoded on chromosome 7q3 are also candi-
dates for disease-causing mutations. The dominant cardiac mus-
40 cM carinic cholinergic receptor (CHRM2, 34) is developmentally
expressed in the atrioventricular ring and myocardium. Muta-
tions in this receptor could exert abnormal trophic effects at5S483 075550
various stages in cardiogenesis and adult life. Similar effects
might be proposed for the constitutive endothelial NO synthase
(35, 36). We anticipate that elucidation of the defect responsi-
- ~ ble for FHC and WPW will contribute to our understanding of
the mechanism relating anomalous AV pathways and ventricu-
lar hypertrophy and will offer insights into normal pathways of
cardiac development.
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